• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PACB

    Pacific Biosciences of California Inc.

    Subscribe to $PACB
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

    IPO Year: 2010

    Exchange: NASDAQ

    Website: pacb.com

    Peers

    $BNGO
    $ILMN

    Recent Analyst Ratings for Pacific Biosciences of California Inc.

    DatePrice TargetRatingAnalyst
    11/11/2024Buy → Neutral
    UBS
    6/3/2024$4.00Buy
    Jefferies
    4/22/2024Overweight → Neutral
    JP Morgan
    4/18/2024$7.00 → $2.50Buy → Neutral
    Goldman
    12/14/2023$11.00Overweight
    Stephens
    12/14/2023Neutral
    Guggenheim
    12/13/2023Peer Perform
    Wolfe Research
    11/17/2023$13.00 → $10.00Neutral → Buy
    UBS
    10/31/2023$11.00Neutral → Overweight
    Cantor Fitzgerald
    9/28/2023$11.00Outperform
    Bernstein
    See more ratings

    Pacific Biosciences of California Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PacBio Announces First Quarter 2025 Financial Results

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results:  Q1 2025Q1 2024Revenue$37.2 million$38.8 millionInstrument revenue$11.0 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio™ systems1228Vega™ systems28—Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspon

      5/8/25 4:15:34 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand

      MENLO PARK, Calif. and BANGKOK, May 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) a leading provider of high-quality, highly accurate sequencing platforms, and Chulalongkorn University, a national leader in genomic and translational research, today announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) as part of a newborn screening research program. This marks the first initiative in Asia Pacific to explore the use of PacBio's HiFi sequencing technology at population scale - an effort designed to evaluate how comprehensive genomic data can support earlier, more accurate identification of rare and treatable conditions in newborns. The collaboration h

      5/5/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Plans to Improve Methylation Detection in HiFi Chemistry

      MENLO PARK, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced it plans to improve on its already highly accurate methylation detection capabilities in HiFi chemistry through licensing advanced DNA methylation detection methods developed by Professor Dennis Lo and colleagues at the The Chinese University of Hong Kong (CUHK) and Centre for Novostics. The licensed technology is designed to enhance PacBio HiFi sequencing with improved detection of DNA base modifications—including 5-hydroxymethylcytosine (5hmC) and hemimethylated 5-methylcytosine (5mC)—in native DNA. PacBio plans to bring th

      4/28/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Davos Alzheimer's Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer's Disease Research in North Africa

      MENLO PARK, Calif. and GENEVA, Switzerland , April 22, 2025 (GLOBE NEWSWIRE) -- The Davos Alzheimer's Collaborative (DAC), a global initiative to prevent Alzheimer's disease and improve brain health, today announced that PacBio (NASDAQ:PACB), a leader in high-quality, highly-accurate long-read sequencing platforms, will be a technology partner to its North African Dementia Registry (NADR) project. Spearheaded by DAC, this effort brings together The Institute of Global Health and Human Ecology (I-GHHE) at The American University in Cairo (AUC) and UCL Queen Square Institute of Neurology, University College London (UCL), and aims to develop a high-quality, comprehensive multi-omics dataset t

      4/22/25 9:04:59 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

      Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. Preliminary First Quarter Results  Preliminary Q1 2025Q1 2024Revenue$36.9 million$38.8 millionInstrument revenue$10.8 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio systems1228Vega systems28-Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9

      4/9/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Grants Equity Incentive Award to New Employee

      MENLO PARK, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering 342,432 shares of PacBio common stock to the Company's recently hired Chief Financial Officer, Jim Gibson, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the "2020 Inducement Plan"), effective on March 31, 2025. The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4). The Op

      4/4/25 7:45:41 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jim Gibson to join PacBio as Chief Financial Officer

      MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company's new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley's most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations. Mr. Gibson joins PacBio from Sequoia, a strategic compensation and benefits solutions provider, where he served as CFO across

      3/27/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Scientists Solve One of Genomics' Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes

      MENLO PARK, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in Nature Communications unveiling a powerful new method for analyzing some of the most complex regions of the human genome. Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts, the study utilizes Paraphase, an informatics tool that, when paired with HiFi long-read sequencing, allows for high-precision variant detection and copy number analysis in 316 previously inaccessible segmental duplication regions, including 9 challenging medically-relevant genes. Segmental dupli

      3/17/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio to Participate in TD Cowen's 45th Annual Health Care Conference

      MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 PM ET (12:10 PM PT) in Boston, MA. A live webcast of the event can be accessed at the company's investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event. About PacBio PacBio (NASDAQ:PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clini

      2/19/25 4:05:00 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Grants Equity Incentive Award to New Employee

      MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering 400,000 shares of PacBio common stock, and restricted stock units ("RSUs") covering 300,000 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the "2020 Inducement Plan"), effective on February 10, 2025. The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance wi

      2/14/25 11:09:09 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Pacific Biosciences of California Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Meline David W bought $176,160 worth of shares (40,000 units at $4.40) (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      3/6/24 5:36:07 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Pacific Biosciences of California Inc. SEC Filings

    See more
    • Pacific Biosciences of California Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      5/8/25 4:19:09 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pacific Biosciences of California Inc.

      SCHEDULE 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      4/30/25 11:13:15 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Pacific Biosciences of California Inc.

      DEFA14A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      4/23/25 4:41:05 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Pacific Biosciences of California Inc.

      DEF 14A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      4/23/25 4:38:37 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pacific Biosciences of California Inc.

      SCHEDULE 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      4/9/25 4:09:14 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pacific Biosciences of California Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      4/9/25 9:08:37 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      3/27/25 9:07:47 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form S-8 filed by Pacific Biosciences of California Inc.

      S-8 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      3/17/25 8:58:18 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-K filed by Pacific Biosciences of California Inc.

      10-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      3/17/25 8:32:07 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pacific Biosciences of California Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      3/13/25 4:06:34 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Pacific Biosciences of California Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Gibson James R Ii was granted 1,000,000 shares (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      4/2/25 4:18:38 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 3 filed by new insider Gibson James R Ii

      3 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      4/2/25 4:09:07 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Farmer Michele was granted 89,835 shares, increasing direct ownership by 49% to 274,454 units (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      3/21/25 4:55:45 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Van Oene Mark was granted 449,176 shares, increasing direct ownership by 30% to 1,946,871 units (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      3/21/25 4:54:12 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Henry Christian O was granted 920,810 shares, increasing direct ownership by 41% to 3,146,167 units (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      3/21/25 4:52:55 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Henry Christian O sold $17,583 worth of shares (12,497 units at $1.41), decreasing direct ownership by 0.56% to 2,225,357 units (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      3/5/25 4:37:39 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Van Oene Mark sold $9,126 worth of shares (6,486 units at $1.41), decreasing direct ownership by 0.43% to 1,497,695 units (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      3/5/25 4:37:01 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Farmer Michele sold $4,183 worth of shares (2,973 units at $1.41), decreasing direct ownership by 2% to 184,619 units (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      3/5/25 4:36:15 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Farmer Michele sold $45,727 worth of shares (24,349 units at $1.88), decreasing direct ownership by 11% to 187,592 units (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      2/19/25 5:00:17 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Van Oene Mark sold $189,252 worth of shares (100,773 units at $1.88), decreasing direct ownership by 6% to 1,496,681 units (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      2/19/25 4:59:37 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Pacific Biosciences of California Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Pacific Biosciences of California Inc.

      SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/26/24 8:27:01 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Pacific Biosciences of California Inc.

      SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/14/24 5:52:54 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Pacific Biosciences of California Inc.

      SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/14/24 5:48:11 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Pacific Biosciences of California Inc.

      SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/12/24 4:43:51 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Pacific Biosciences of California Inc.

      SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/8/24 4:16:42 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Pacific Biosciences of California Inc.

      SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/4/24 10:47:06 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Pacific Biosciences of California Inc. (Amendment)

      SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      2/13/24 4:15:44 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Pacific Biosciences of California Inc. (Amendment)

      SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      2/12/24 5:12:09 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Pacific Biosciences of California Inc. (Amendment)

      SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      2/9/24 6:42:26 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Pacific Biosciences of California Inc. (Amendment)

      SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      2/5/24 6:08:57 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Pacific Biosciences of California Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pacific Biosciences downgraded by UBS

      UBS downgraded Pacific Biosciences from Buy to Neutral

      11/11/24 9:44:33 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies resumed coverage on Pacific Biosciences with a new price target

      Jefferies resumed coverage of Pacific Biosciences with a rating of Buy and set a new price target of $4.00

      6/3/24 8:16:36 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pacific Biosciences downgraded by JP Morgan

      JP Morgan downgraded Pacific Biosciences from Overweight to Neutral

      4/22/24 7:40:44 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pacific Biosciences downgraded by Goldman with a new price target

      Goldman downgraded Pacific Biosciences from Buy to Neutral and set a new price target of $2.50 from $7.00 previously

      4/18/24 7:36:54 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Stephens initiated coverage on Pacific Biosciences with a new price target

      Stephens initiated coverage of Pacific Biosciences with a rating of Overweight and set a new price target of $11.00

      12/14/23 7:43:16 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Guggenheim initiated coverage on Pacific Biosciences

      Guggenheim initiated coverage of Pacific Biosciences with a rating of Neutral

      12/14/23 7:42:55 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wolfe Research initiated coverage on Pacific Biosciences

      Wolfe Research initiated coverage of Pacific Biosciences with a rating of Peer Perform

      12/13/23 7:50:07 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pacific Biosciences upgraded by UBS with a new price target

      UBS upgraded Pacific Biosciences from Neutral to Buy and set a new price target of $10.00 from $13.00 previously

      11/17/23 7:44:08 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pacific Biosciences upgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald upgraded Pacific Biosciences from Neutral to Overweight and set a new price target of $11.00

      10/31/23 9:57:33 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bernstein initiated coverage on Pacific Biosciences with a new price target

      Bernstein initiated coverage of Pacific Biosciences with a rating of Outperform and set a new price target of $11.00

      9/28/23 7:35:09 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Pacific Biosciences of California Inc. Financials

    Live finance-specific insights

    See more
    • PacBio Announces First Quarter 2025 Financial Results

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results:  Q1 2025Q1 2024Revenue$37.2 million$38.8 millionInstrument revenue$11.0 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio™ systems1228Vega™ systems28—Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspon

      5/8/25 4:15:34 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

      Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. Preliminary First Quarter Results  Preliminary Q1 2025Q1 2024Revenue$36.9 million$38.8 millionInstrument revenue$10.8 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio systems1228Vega systems28-Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9

      4/9/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results

      MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue of $39.2 million, a 33% decrease compared with $58.4 million in the prior-year period.Instrument revenue of $15.3 million compared with $35.1 million in the prior-year period. Instrument revenue in the fourth quarter of 2024 included 23 Revio® sequencing systems and 7 Vega™ sequencing systems.Consumables revenue of $18.8 million compared with $18.9 million in the prior-year period.Service and other revenue of $5.1 million compared with $4.4 million in the prior-year period. Gross margin, opera

      2/13/25 4:05:00 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025

      MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thursday, February 13, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, February 13, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the

      1/30/25 4:05:00 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

      Commenced shipment of the Vega™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$500 HiFi genome on the Revio® system MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2024 and full year 2024 of $39.2 million and $154.0 million representing a year-over-year decline of 33% and 23%, respectively. "Though challenging, 2024 was a productive year for PacBio as we launched groundbreaking products, strengthened our balance sheet, and made significant pr

      1/14/25 9:00:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Third Quarter 2024 Financial Results

      MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended September 30, 2024. Third quarter results: Revenue of $40.0 million compared with $55.7 million in the prior-year period.Instrument revenue of $16.8 million compared with $34.7 million in the prior-year period. Instrument revenue in the third quarter of 2024 included 22 Revio™ sequencing systems.Consumables revenue of $18.5 million compared with $16.9 million in the prior-year period.Service and other revenue of $4.7 million compared with $4.1 million in the prior-year period. Gross profit, operating expenses, net loss, and net loss per share are reported on

      11/7/24 4:05:00 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024

      MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thursday, November 7, 2024, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, November 7, 2024, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the "PacBio

      10/10/24 4:05:00 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Second Quarter 2024 Financial Results

      MENLO PARK, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended June 30, 2024. Second quarter results: Revenue of $36.0 million compared with $47.6 million in the prior-year period.Instrument revenue of $14.7 million compared with $29.9 million in the prior-year period. Instrument revenue in the second quarter of 2024 included 24 Revio™ sequencing systems.Consumables revenue of $17.0 million compared with $13.7 million in the prior-year period.Service and other revenue of $4.3 million compared with $3.9 million in the prior-year period. Gross profit for the second quarter of 2024 was $5.9 million, which included $4.6 mil

      8/7/24 4:05:00 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio to Report Second Quarter 2024 Financial Results on August 7, 2024

      MENLO PARK, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Wednesday, August 7, 2024, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the "PacBio Q

      7/15/24 4:03:00 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces First Quarter 2024 Financial Results

      MENLO PARK, Calif., May 9, 2024 /PRNewswire/ -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended March 31, 2024. First quarter results: Revenue of $38.8 million compared with $38.9 million in the prior-year period.Instrument revenue of $19.0 million compared with $20.7 million in the prior-year period. Instrument revenue in the first quarter of 2024 included 28 RevioTM sequencing systems.Consumables revenue of $16.0 million compared with $14.0 million in the prior-year period.Service and other revenue of $3.8 million compared with $4.2 million in th

      5/9/24 4:05:00 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Pacific Biosciences of California Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Jim Gibson to join PacBio as Chief Financial Officer

      MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company's new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley's most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations. Mr. Gibson joins PacBio from Sequoia, a strategic compensation and benefits solutions provider, where he served as CFO across

      3/27/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service

      MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences sectors. Prior to joining PacBio, he served as Senior Vice President, North America for Sinch AB, a leading global provider of cloud-based communication solutions for business and mobile operators. In his role he led North American sales for the enterprise, mid-market segments. Before that, he held senior sales positions at Zoom V

      2/3/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Appointment of Chris Smith to Board of Directors

      MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company. Mr. Smith, a seasoned executive with extensive experience in the life sciences and healthcare industries, brings a strong track record of leadership in genomics, diagnostics, and corporate strategy. As CEO of NeoGenomics, a leading provider of oncology testing services, he has overseen the company's continued growth and in

      1/30/25 9:05:00 AM ET
      $NEO
      $PACB
      Precision Instruments
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces the Retirement of David Botstein, Ph.D., from its Board of Directors

      MENLO PARK, Calif., Dec. 11, 2023 /PRNewswire/ -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that David Botstein, Ph.D., a member of PacBio's Board of Directors, has retired from his position effective December 7, 2023.   "I would like to thank David for his dedication to PacBio since he joined the Board in 2012," said Christian Henry, President and Chief Executive Officer. "His deep understanding of genomics and broad experience in technological innovation in the field has made him a valuable leader as PacB

      12/11/23 8:00:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces the Appointment of Olga Troyanskaya from Princeton University to the Scientific Advisory Board

      Current Member, Jay Shendure, is Appointed Chair   MENLO PARK, Calif., May 30, 2023 /PRNewswire/ -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Olga Troyanskaya, Ph.D., Professor of Computer Science and the Lewis Sigler Institute for Integrative Genomics at Princeton University to PacBio's Scientific Advisory Board (SAB) and Jay Shendure, Ph.D. as Chair. Dr. Shendure is a Professor of Genome Sciences at the University of Washington. "I am so honored to have Dr. Troyanskaya join PacBio's Sci

      5/30/23 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Resolve Biosciences Announces Appointment of John Stark as Chief Executive Officer

      Life sciences tools veteran brings decades of experience leading successful teams, commercializing industry-defining technology platforms, and scaling global organizations Resolve Biosciences, a company pioneering Molecular Cartography™ technology, announced today that it has appointed John Stark as Chief Executive Officer. As part of this transition, Resolve Biosciences' previous CEO, Jason Gammack, will be leaving the company. Mr. Stark brings more than 20 years of experience commercializing early-stage technologies, scaling organizations, and navigating capital markets for some of the most innovative life sciences companies. Most recently, Mr. Stark was Chief Executive Officer of Quant

      3/15/23 7:58:00 AM ET
      $BIO
      $PACB
      $QSI
      $TMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Industrial Machinery/Components
    • PacBio Announces Appointment of Genomics Industry Veteran Jeff Eidel as Chief Commercial Officer

      MENLO PARK, Calif., July 21, 2022 /PRNewswire/ -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Jeff Eidel as Chief Commercial Officer, effective August 16, 2022. In this role, Mr. Eidel will have global responsibility for all commercial activity including sales, marketing, and customer support. "Jeff is a strong leader and an incredible executive, and I expect him to have a significant impact on the entire organization," said Christian Henry, President and Chief Executive Officer of PacBio.

      7/21/22 9:00:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer

      CAMBRIDGE, United Kingdom, June 14, 2022 (GLOBE NEWSWIRE) -- Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is revolutionizing genome sequencing, today announced the appointment of Peter J. Fromen as Chief Executive Officer effective July 18, 2022. Gail Marcus who has been acting Chief Executive Officer since 2020 will continue as Chair of the Board. Professor Sir Shankar Balasubramanian FRS, co-founder of Cambridge Epigenetix, said, "We welcome Peter and his vast industry experience and valuable relationships to lead Cambridge Epigenetix at this critical juncture. The founders, Gail and the entire Board are delighted to have Peter's leadership as we see

      6/14/22 9:00:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Organogenesis Appoints Prathyusha Duraibabu to Board of Directors

      CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company's Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. "Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positio

      11/22/21 7:00:00 AM ET
      $ORGO
      $PACB
      $SGMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pacific Biosciences Further Expands Leadership Team with Appointment of Dr. Catherine Ball to Newly Created Position of Senior Vice President of Research

      MENLO PARK, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing platforms, today announced the appointment of three new hires to its growing team. Dr. Catherine Ball joins the company as Senior Vice President of Research, Kathleen Lynch joins as Head of Global Government Affairs and Corporate Communications, and Michele Farmer joins as Chief Accounting Officer. Dr. Ball is a product of the California education system having completed her PhD in Molecular Biology at UCLA and her Postdoctoral research at Berkeley prior to 17 years at Stanford. Most recently, she was the Chief Scientific Offi

      5/17/21 4:05:00 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials